Lurasidone
- Generic Name
- Lurasidone
- Brand Names
- Latuda
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O2S
- CAS Number
- 367514-87-2
- Unique Ingredient Identifier
- 22IC88528T
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.
- Associated Conditions
- Depression, Bipolar, Schizophrenia
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 1
- Registration Number
- NCT03902613
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 210
- Registration Number
- NCT03465787
- Locations
- 🇰🇷
Borame Medical Center, Seoul, Seoul, Dongjak-gu, Korea, Republic of
NRX101 Glx Biomarker Validation Study
- Conditions
- Bipolar DepressionSuicidal Ideation
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03402152
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
- Conditions
- Bipolar DepressionSuicidal Ideation
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03396068
- Locations
- 🇺🇸
JP Smith Hospital, Fort Worth, Texas, United States
🇺🇸Research Site, Birmingham, Birmingham, Alabama, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
- Conditions
- Bipolar DepressionSuicidal Ideation and Behavior
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03395392
- Locations
- 🇺🇸
iResearch Atlanta, LLC, Decatur, Georgia, United States
🇺🇸iResearch Savannah, Savannah, Georgia, United States
🇺🇸Peace Health Medical Group, Eugene, Oregon, United States
A Study of Lurasidone HCl in Subjects With Schizophrenia
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Standard Chem. & Pharm. Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT03393026
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
🇨🇳Taipei City Hospital, Songde Branch, Taipei, Taiwan
Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Target Recruit Count
- 100
- Registration Number
- NCT03304457
- Locations
- 🇮🇳
AIIMS, Bhubaneshwar, Odisha, India
Sequential Therapy for the Treatment of Severe Bipolar Depression.
- Conditions
- Bipolar DepressionSuicidal IdeasSuicidal IdeationSuicide, Attempted
- Interventions
- Drug: NRX-101 Oral CapsuleDrug: Saline Solution Intravenous Infusion
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02974010
- Locations
- 🇺🇸
Research Site, Birmingham, Birmingham, Alabama, United States
🇺🇸Research Site, Charlotte, Charlotte, North Carolina, United States
🇺🇸Research Site, Houston, Houston, Texas, United States
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Conditions
- Bipolar Disorder
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1037352
- Registration Number
- NCT02893371
- Locations
- 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.